Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies

Figure 2

Chimeric antigen receptor (CAR) T-cell-based adoptive immunotherapeutics in hematological malignancies and its targeted recognition on tumor cells in an HLA-independent manner. (a) Flow chart of CAR-T-cell-based adoptive immunotherapeutics. Peripheral blood T-cells isolated from a patient with hematological malignancy are subjected to genetic modification with a relevant CAR that can target the surface antigens of malignant cells. Subsequently, the CAR-modified T-cells are subjected to ex vivo expansion and then administered via adoptive transfer to the patient. (b) Tumor cells are recognized and killed by CAR-T-cells in an HLA-independent manner; antitumor immunity can be enhanced and optimized through genome editing and gene transfer technologies.

(a)

(b)